Home › NDC Lookup › Ingredients › Methocarbamol › 43547-0226-10
⚪image loading
(from DailyMed)

Methocarbamol 750 mg Tablet, 100-count — NDC 43547-226-10 (Billing 43547-0226-10)

by Solco Healthcare LLC · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of Methocarbamol 750 mg Tablet from Solco Healthcare LLC, marketed since Jan 2013 and currently FDA-listed; retail pharmacies pay about $0.0431 per tablet (NADAC).

NDC 43547-0226-10
🏷️ FDA NDC (as labeled) 43547-226-10 billing pads the product segment with a zero
This package
Contains100-count Cost per ea$0.0431 NADAC Per package$4.31 / 100 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.1403/unit — full pricing hub ↓
Product page 43547-0226-50 Also comes in: 500 tablets 43547-226-50
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Methocarbamol (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Mar 21, 2025 — Lack of Assurance of Sterility: Media fill with bacterial contamination (Somerset Therapeutics Private Limited) · FDA recall D-0354-2025
Class I · Feb 15, 2024 — Presence of Particulate Matter (Eugia US LLC) · FDA recall D-0440-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 43547-226-10
Product NDC 43547-226
11-digit billing NDC 43547022610
NCPDP billing unit EA — each (per item)
RxCUI 197943, 197944
UNII 125OD7737X
UPC 0343547226107, 0343547405106
Application # ANDA086988
SPL Set ID 32863f21-30ff-4a8b-a2e6-8ab14a37af0d
Established class (EPC) Muscle Relaxant
Physiologic effect Centrally-mediated Muscle Relaxation
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2013-01-15
Route ORAL
Dosage form TABLET
Substance METHOCARBAMOL
TE code (Orange Book) AA · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 75100070000310
GPI class Methocarbamol
GCN Seq No 004655
GCN 17893
HICL code 001938
Ingredient (HICL) Methocarbamol
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6H
Therapeutic class — specific (HIC3) Skeletal Muscle Relaxants
AHFS code 12:20.04.00
AHFS class Centrally Acting Skeletal Muscle Relaxnt
FDB label name METHOCARBAMOL 750 MG TABLET
FDB brand name Methocarbamol
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 004655
  • GCN: 17893
  • GPI-14 (Medi-Span): 75100070000310
  • HICL (First Databank): 001938
  • AHFS class code: 12:20.04.00
  • RxCUI (RxNorm): 197943
Why two NDCs? The FDA registers this code as 43547-226-10 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 43547-0226-10. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Muscle Relaxant class.

Pharmacologic class Muscle Relaxant
Drug family (ATC) Carbamic acid esters
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name METHOCARBAMOL 750 MG TABLET Ingredient Methocarbamol
📗 Our plain-language guide HelloPharmacist
  • It's used along with rest and physical therapy to ease discomfort from sudden, painful muscle and bone conditions. It's an add-on, not a replacement for those other measures.
  • It's best to avoid it. Methocarbamol can add to the effects of alcohol and other sedating medicines. Deaths have been reported with overdose, including when alcohol was involved.
  • Be careful. It can affect your mental and physical abilities. Wait until you know how it affects you before driving or using machinery.
  • Tablets and Atmeksi suspension are taken by mouth several times a day. Usually a higher amount is used for the first couple of days, then less. If you use Atmeksi, shake it well fo...
📖 Read our full Methocarbamol guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.043 $4.31 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.1403 $14.03 / 100 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.093 $0.042
▼ Down 53% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
43547-0226-10 You're viewing this 100 TABLET in 1 BOTTLE $0.0431 / ea $4.31 2013-01-15 — Active
43547-0226-50 43547-226-50 Main listing 500 TABLET in 1 BOTTLE $0.0431 / ea $21.56 2013-01-15 — Active

You're viewing the smallest of 2 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0431 NADAC).

This pack accounts for about 2.4% of this product's recent Medicaid fills; most go to the 500 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet in 1 bottle.
How does this package differ from NDC 43547-0226-50?
Both are Methocarbamol 750 mg Tablet — the drug itself is identical. This page's package is the 100-count one, while NDC 43547-0226-50 is the 500 tablets package.
What NDC number is used to bill for this package of Methocarbamol 750 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Methocarbamol 750 mg 00904-7058-61 Major 100 tablets $0.043 AA Availability likely —
Methocarbamol 750 mg 31722-0534-01 Camber 1200 tablets $0.043 AA Availability likely —
Methocarbamol 750 mgthis 43547-0226-10 Solco 100 tablets $0.043 AA Availability likely —
Methocarbamol 750 mg 50268-0521-15 AvPAK 50 tablets $0.043 AA Availability likely —
Methocarbamol 750 mg 59651-0341-01 Aurobindo 100 tablets $0.043 AA Availability likely —
Methocarbamol 750 mg 60687-0568-01 American 100 tablets $0.043 AA Availability likely —
Methocarbamol Tablets, USP, 750 mg 63561-0174-01 Granulation 100 tablets $0.043 AA Availability likely —
Methocarbamol 750 mg 70010-0770-01 Granules 100 tablets $0.043 AA Availability likely —
Methocarbamol 750 mg 76385-0124-01 UNICHEM 100 tablets $0.043 AA Availability likely —
Methocarbamol 750 mg 00615-8507-39 NCS 30 tablets — AA FDA listed —
Methocarbamol Tablets, USP, 750 mg 10135-0723-01 Marlex 100 tablets — AA FDA listed —
Methocarbamol 750 mg 35561-0211-12 Bostal 100 tablets — AA FDA listed —
Methocarbamol 750 mg 43063-0905-14 PD-Rx 14 tablets — AA FDA listed —
Methocarbamol 750 mg 50090-1781-00 A-S 20 tablets — AA FDA listed —
Methocarbamol 750 mg 50090-1783-00 A-S 90 tablets — AA FDA listed —
Methocarbamol 750 mg 50090-3556-00 A-S 20 tablets — AA FDA listed —
Methocarbamol 750 mg 50090-3587-00 A-S 90 tablets — AA FDA listed —
Methocarbamol 750 mg 50090-5006-00 A-S 90 tablets — AA FDA listed —
Methocarbamol 750 mg 50090-5008-00 A-S 20 tablets — AA FDA listed —
Methocarbamol 750 mg 51407-0468-01 Golden 100 tablets — AA FDA listed —
Methocarbamol 750 mg 51655-0205-20 Northwind 20 tablets — AA FDA listed —
Methocarbamol 750 mg 51655-0575-20 Northwind 20 tablets — AA FDA listed —
Methocarbamol 750 mg 55154-2130-00 Cardinal 10 tablets — AA FDA listed —
Methocarbamol 750 mg 55154-2335-00 Cardinal 10 tablets — AA FDA listed —
Methocarbamol 750 mg 60760-0725-28 St. 28 tablets — AA FDA listed —
Methocarbamol 750 mg 60760-0770-28 St. 28 tablets — AA FDA listed —
Methocarbamol 750 mg 61919-0616-30 DIRECT 30 tablets — AA FDA listed —
Methocarbamol 750 mg 62207-0770-41 Granules 24 tablets — AA FDA listed —
Methocarbamol 750 mg 63187-0019-00 Proficient 100 tablets — AA FDA listed —
Methocarbamol 750 mg 63187-0130-30 Proficient 30 tablets — AA FDA listed —
Methocarbamol 750 mg 63629-2419-01 Bryant 500 tablets — AA FDA listed —
Methocarbamol 750 mg 63629-2420-01 Bryant 100 tablets — AA FDA listed —
Methocarbamol 750 mg 63629-8995-01 Bryant 30 tablets — AA FDA listed —
Methocarbamol 750 mg 66267-0146-12 NuCare 12 tablets — AA FDA listed —
Methocarbamol 750 mg 66267-0803-06 NuCare 6 tablets — AA FDA listed —
Methocarbamol 750 mg 67046-1147-03 Coupler 30 tablets — AA FDA listed —
Methocarbamol 750 mg 67296-2203-01 Redpharm 15 tablets — AA FDA listed —
Methocarbamol 750 mg 68071-3859-02 NuCare 20 tablets — AA FDA listed —
Methocarbamol 750 mg 68071-4505-01 NuCare 21 tablets — AA FDA listed —
Methocarbamol 750 mg 68788-7980-03 Preferred 30 tablets — AA FDA listed —
Methocarbamol 750 mg 68788-8172-03 Preferred 30 tablets — AA FDA listed —
Methocarbamol 750 mg 68788-8876-03 Preferred 30 tablets — AA FDA listed —
Methocarbamol 750 mg 69584-0612-09 Oxford 90 tablets — AA FDA listed —
Methocarbamol 750 mg 70518-1738-04 REMEDYREPACK 30 tablets — AA FDA listed —
Methocarbamol 750 mg 70518-4472-00 REMEDYREPACK 90 tablets — AA FDA listed —
Methocarbamol 750 mg 70518-4501-00 REMEDYREPACK 40 tablets — AA FDA listed —
Methocarbamol 750 mg 70868-0901-90 Key 90 tablets — AA FDA listed —
Methocarbamol 750 mg 71205-0068-20 Proficient 20 tablets — AA FDA listed —
Methocarbamol 750 mg 71205-0285-30 Proficient 30 tablets — AA FDA listed —
Methocarbamol 750 mg 71335-0251-00 Bryant 14 tablets — AA FDA listed —
Methocarbamol 750 mg 71335-0828-00 Bryant 14 tablets — AA FDA listed —
Methocarbamol 750 mg 71335-1727-00 Bryant 14 tablets — AA FDA listed —
Methocarbamol 750 mg 71335-2305-00 Bryant 14 tablets — AA FDA listed —
Methocarbamol 750 mg 71335-2795-00 Bryant 14 tablets — AA FDA listed —
Methocarbamol 750 mg 71610-0134-53 Aphena 60 tablets — AA FDA listed —
Methocarbamol 750 mg 71610-0174-53 Aphena 60 tablets — AA FDA listed —
Methocarbamol 750 mg 71610-0598-53 Aphena 60 tablets — AA FDA listed —
Methocarbamol 750 mg 71610-0833-30 Aphena 30 tablets — AA FDA listed —
Methocarbamol 750 mg 72162-1930-01 Bryant 100 tablets — AA FDA listed —
Methocarbamol Tablets, USP, 750 mg 72162-2488-01 Bryant 100 tablets — AA FDA listed —
Methocarbamol 750 mg 72789-0022-01 PD-Rx 100 tablets — AA FDA listed —
Methocarbamol 750 mg 72789-0041-20 PD-Rx 20 tablets — AA FDA listed —
Methocarbamol 750 mg 72789-0398-01 PD-Rx 100 tablets — AA FDA listed —
Methocarbamol 750 mg 72789-0429-20 PD-Rx 20 tablets — AA FDA listed —
Methocarbamol Tablets, USP, 750 mg 72789-0521-20 PD-Rx 20 tablets — AA FDA listed —
Methocarbamol 750 mg 72865-0234-01 XLCare 100 tablets — AA FDA listed —
Methocarbamol 750 mg 76420-0040-30 Asclemed 30 tablets — AA FDA listed —
Methocarbamol 750 mg 76420-0258-10 Asclemed 100 tablets — AA FDA listed —
Methocarbamol 750 mg 76420-0638-01 Asclemed 100 tablets — AA FDA listed —
Methocarbamol 750 mg 76420-0894-01 Asclemed 100 tablets — AA FDA listed —
Methocarbamol 750 mg 80425-0020-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 750 mg 80425-0021-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 750 mg 80425-0171-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 750 mg 80425-0490-01 Advanced 30 tablets — AA FDA listed —
Methocarbamol 750 mg 82804-0955-00 Proficient 100 tablets — AA FDA listed —
Methocarbamol 750 mg 82982-0038-40 Pharmasource 40 tablets — AA FDA listed —
Methocarbamol 750 mg 85509-1341-03 PHOENIX 30 tablets — AA FDA listed —
Methocarbamol 750 mg 85509-1770-03 PHOENIX 30 tablets — AA FDA listed —
Methocarbamol 750 mg 85766-0060-01 Sportpharm 100 tablets — AA FDA listed —
Methocarbamol 750 mg 87063-0041-01 Asclemed 100 tablets — AA FDA listed —
Methocarbamol 750 mg 87063-0689-12 ASCLEMED 120 tablets — AA FDA listed —
Methocarbamol 750 mg 85534-0022-00 HAWAII 30 tablets — AA FDA listed —
Methocarbamol 750 mg 60760-0875-28 St. 28 tablets — AA FDA listed —
Methocarbamol 750 mg 82461-0723-90 Medcore 90 tablets — AA FDA listed —
Methocarbamol 750 mg 53401-0035-53 Aphena 60 tablets — AA FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2013
On the market since
Jan 2013
📍
2026
Currently FDA-listed
13 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerSolco Healthcare LLC
Application holderPRINSTON PHARMACEUTICAL INC
FDA applicationANDA086988 (ANDA)
Labeler code43547
First marketedJan 2013
Product typeHuman Prescription Drug
Portfolio41 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🔄 Drug / Laboratory Test Interactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 🧬 Pharmacokinetics 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 58 words ▾

INDICATIONS AND USAGE Methocarbamol tablets, USP are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Methocarbamol does not directly relax tense skeletal muscles in man.

⏱️ Dosage and Administration 79 words ▾

DOSAGE AND ADMINISTRATION Methocarbamol tablets USP, 500 mg – Adults: Initial dosage: 3 tablets q.i.d. Maintenance dosage: 2 tablets q.i.d. Methocarbamol tablets USP, 750 mg – Adults: Initial dosage: 2 tablets q.i.d.

Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d. Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered).

Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

⛔ Contraindications 18 words ▾

CONTRAINDICATIONS Methocarbamol tablets, USP are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

⚠️ Warnings 156 words ▾

WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol.

Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see PRECAUTIONS, Pregnancy ). Use In Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

🤒 Adverse Reactions 82 words ▾

ADVERSE REACTIONS Adverse reactions reported coincident with the administration of methocarbamol include: Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting Hemic and lymphatic system: Leukopenia Immune system: Hypersensitivity reactions Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria

🔄 Drug Interactions 36 words ▾

Drug interactions See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol. Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.

🔄 Drug / Laboratory Test Interactions 33 words ▾

Drug/laboratory test interactions Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

🤰 Pregnancy 195 words ▾

Pregnancy Teratogenic effects - Pregnancy Category C Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol tablets, USP should be given to a pregnant woman only if clearly needed.

Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS ).

Nursing mothers Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol tablets, USP are administered to a nursing woman. Pediatric use Safety and effectiveness of Methocarbamol tablets, USP in pediatric patients below the age of 16 have not been established.

🧒 Pediatric Use 21 words ▾

Pediatric use Safety and effectiveness of Methocarbamol tablets, USP in pediatric patients below the age of 16 have not been established.

🆘 Overdosage 101 words ▾

OVERDOSAGE Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma. In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.

Treatment Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.

🧬 Clinical Pharmacology 45 words ▾

CLINICAL PHARMACOLOGY The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.

📦 How Supplied / Storage and Handling 109 words ▾

HOW SUPPLIED Methocarbamol tablets, USP 500 mg tablets are round standard convex, scored, white to off-white tablet, debossed “S” above the bisect and “225” below on one side and plain on the reverse side. They are supplied as follows: Bottles of 100 NDC 43547-405-10 Bottles of 500 NDC 43547-405-50 Methocarbamol tablets, USP 750 mg tablets are capsule shape, white to off-white tablet, debossed “S226” on one side and plain on the reverse side. They are supplied as follows: Bottles of 100 NDC 43547-226-10 Bottles of 500 NDC 43547-226-50 Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F). [see USP Controlled Room Temperature].

Dispense in tight container.

📦 Storage and Handling 21 words ▾

Store at controlled room temperature, between 20°C and 25°C (68°F and 77°F). [see USP Controlled Room Temperature]. Dispense in tight container.

📋 Description 120 words ▾

DESCRIPTION Methocarbamol tablets, USP, a carbamate derivative of guaifenesin, are a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties. The chemical name of methocarbamol is 3-(2-meth-oxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C 11 H 15 NO 5 . Its molecular weight is 241.24.

The structural formula is shown below. Methocarbamol, USP is a white powder, sparingly soluble in water and chloroform, soluble in alcohol (only with heating) and propylene glycol, and insoluble in benzene and n -hexane. Methocarbamol tablets, USP are available as 500 mg and 750 mg tablets for oral administration.

Methocarbamol tablets USP, 500 mg and 750 mg contain the following inactive ingredients: magnesium stearate, povidone, and sodium starch glycolate. Figure 1 structural formula

💬 Information for Patients 46 words ▾

Information for patients Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery. Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS Information for patients Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery. Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants. Drug interactions See WARNINGS and PRECAUTIONS for interaction with CNS drugs and alcohol.

Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents. Drug/laboratory test interactions Methocarbamol may cause a color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

Carcinogenesis, mutagenesis, impairment of fertility Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility. Pregnancy Teratogenic effects - Pregnancy Category C Animal reproduction studies have not been conducted with methocarbamol.

It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Methocarbamol tablets, USP should be given to a pregnant woman only if clearly needed. Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development.

There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see WARNINGS ). Nursing mothers Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk.

Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol tablets, USP are administered to a nursing woman. Pediatric use Safety and effectiveness of Methocarbamol tablets, USP in pediatric patients below the age of 16 have not been established.

🍼 Nursing Mothers 50 words ▾

Nursing mothers Methocarbamol and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Methocarbamol tablets, USP are administered to a nursing woman.

🧬 Pharmacokinetics 69 words ▾

Pharmacokinetics In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and

0.80L/h/kg, the mean plasma elimination half-life ranges between 1 and 2 hours, and the plasma protein binding ranges between 46% and 50%. Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine. Small amounts of unchanged methocarbamol also are excreted in the urine.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 37 words ▾

Carcinogenesis, mutagenesis, impairment of fertility Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed. No studies have been conducted to assess the effect of methocarbamol on mutagenesis or its potential to impair fertility.

📄 Package Label / Principal Display Panel 179 words ▾

Container Label - 750 mg - 100 tablets NDC 43547- 226-10 Rx only Methocarbamol Tablets, USP 750 mg Each tablet contains 750 mg of Methocarbamol, USP. Dosage: See package insert for full prescribing Information. Store at controlled room temperature, between 20℃ and 25℃ (68℉ and 77℉). [see USP Controlled Room Temperature].

Dispense in tight container. Keep this and all drugs out of the reach of children. Manufactured by: Prinston Laboratories Charlotte, NC 28206, USA Distributed by: Solco Healthcare U.S., LLC Somerset, NJ 08873, USA Rev: OTC2025 9040317-05 750 mg 100ct

Container Label - 500 mg - 100 tablets NDC 43547- 405-10 Rx only Methocarbamol Tablets, USP 500 mg Each tablet contains 500 mg of Methocarbamol, USP. Dosage: See package insert for full prescribing Information. Store at controlled room temperature, between 20℃ and 25℃ (68℉ and 77℉). [see USP Controlled Room Temperature].

Dispense in tight container. Keep this and all drugs out of the reach of children. Manufactured by: Prinston Laboratories Charlotte, NC 28206, USA Distributed by: Solco Healthcare U.S., LLC Somerset, NJ 08873, USA Rev: OCT2025 9040315-05 500mg 100ct

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.4K
Units reimbursed last 4 qtrs
88.8K
Gross reimbursed last 4 qtrs
$12.5K
Avg / prescription
$9.04
Avg / unit
$0.1403
Latest quarter Q1 2026
348Rx
Medicaid pays / ea
$0.1403
gross reimbursed
vs
NADAC / ea
$0.0431
acquisition cost
=
Spread
+$0.0972
+226% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
31% FFS 69% MCO
Fee-for-service · 428 Rx Managed care · 950 Rx
State Medicaid map
Alaska: no data reported AK Maine: 1,227 units · 88.0 per 100k residents ME Washington: 1,039 units · 13.3 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 3,489 units · 34.8 per 100k residents MI New York: 11,396 units · 58.2 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: 1,316 units · 41.2 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 1,455 units · 21.2 per 100k residents IN Ohio: 975 units · 8.3 per 100k residents OH Pennsylvania: 7,949 units · 61.3 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 12,414 units · 31.9 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 1,425 units · 23.0 per 100k residents MO Kentucky: 10,715 units · 237 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 10,104 units · 163 per 100k residents MD Connecticut: 1,541 units · 42.6 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 579 units · 5.3 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 18,693 units · 409 per 100k residents LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 840 units · 2.8 per 100k residents TX Florida: 3,636 units · 16.1 per 100k residents FL
Units reimbursed · per 100k residents
2.8409
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Louisiana 409 /100k
2 Kentucky 237 /100k
3 Maryland 163 /100k
4 Maine 88.0 /100k
5 Pennsylvania 61.3 /100k
6 New York 58.2 /100k
7 Connecticut 42.6 /100k
8 Nevada 41.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
500 tablets43547-0226-50 55,287 Rx · $483,076
100 tablets this page43547-0226-10 1,378 Rx · $12,456
Drug total (last 4 qtrs): 56,665 Rx · 3,121,898 units · $495,532 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Methocarbamol — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Methocarbamol. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$13.41M
Claims incl. refills
1.1M
Beneficiaries
734.7K
Spend / beneficiary
$18.26
Spend / claim
$12.07
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 43547-0224-06 · Solco 43547-0268-10 · SOLCO →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.